Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized placebo-controlled trial of MK-1029 added to montelukast in adults with persistent asthma
2015-005054-36Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in persistent asthma comparing MK-1029 + montelukast with Placebo + montelukast (2 arms). Primary endpoint: Change from baseline in FEV1. Started Jul 2016; status: completed.
02
Drugs
MK-1029
03
Conditions
persistent asthma
Beyond the preview
Go deeper on 2015-005054-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005054-36.